Urol. praxi, 2011; 12(6): 340-344

Bone metastasis in prostate cancer, recent recommendations for the administration of bisphosphonates

MUDr.Vít Vachalovský
Urologická klinika 1. LF UK a VFN, Praha

Prostate cancer occupies one of the leading positions in the incidence of cancer among men. A typical feature of this disease is its ability to

metastasize to bones which predisposes the patients to skeletal related events (SRE). New konowledge of the pathophysiology field about

the origin and development of metastases reveal new opportunity in the care for metastatic prostate cancer patients. Bisphosphonates

significantly delay time to first SRE, reduce the risk of multiple events and improve quality of life of the patients. It is possible to use bisphosponates

in prevention and treatment of cancer treatment-induced bone loss in men with androgen deprivation therapy. Bisphosphonates

are also used in prevention of bone metastases in men with early prostate cancer. New medicament denosumab is mentioned too.

Keywords: prostate cancer, bisphosphonates, bone metastases, SRE

Published: December 1, 2011  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Vachalovský V. Bone metastasis in prostate cancer, recent recommendations for the administration of bisphosphonates. Urol. praxi. 2011;12(6):340-344.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Ústav zdravotnických informací a statistiky ČR, Novotvary (Cancer Incidence in the Czech republic), vydáváno každoročně, poslední vydání: rok 2007, dostupné z http://www.uzis.cz).
    2. Adam Z, Křivanová A, Táborská E, et al. Farmakologie a klinický efekt léků inhibujících osteolýzu, bisfosfonátů a preparátů kalcitoninu. In Farmakologická léčba chronické bolesti a patologických osteolytických procesů. Vydala Masarykova univerzita v Brně roku 2000. Produkce a tisk: APV agentura, Brno.
    3. Mayer O. Starší a novější bisfosfonáty v léčbě kostních metastáz - pohled farmakologa. Farmakoterapie, 2008, 2: 236-238.
    4. Aapro M, Abrahamsson PA, Body JJ, et al. Guidance on the use of bisphosphonates in solid tumors: recommendations of an international expert panel. Ann Oncol. 2008; 19(3): 420-432. Go to original source... Go to PubMed...
    5. Heidenreich A, Hofmann R, Engelmann U. The use of bisphosphonates for the palliative treatment of painful bone metastatic due to hormone refractory prostate cancer. J Urol. 2001; 165: 136-140. Go to original source... Go to PubMed...
    6. Dearnaley DP, Mason MD, et al. Adjuvant therapy with oral sodium clodronate in locally advanced and metastatic prostate cancer: Long-term overall survival results from the MRC PRO 4 and PRO 5 randomised controlled trials. Lancet Oncol. 2009; 10: 872-76. Go to original source... Go to PubMed...
    7. Král M, Hrabec M, Grepl M, et al. Praktický přístup k pacientovi s kostními metastázami u urologických nádorů. Urolog. pro Praxi, 2011; 12(1): 12-17.
    8. Saad F, Gleason DM, Murray R, et al. A randomized placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst. 2002; 94: 1458. Go to original source... Go to PubMed...
    9. Saad F, Gleason DM, Murray R, et al. Long term efficacy of zoledronic acid fot the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J Natl Cancer Inst. 2004; 96: 879. Go to original source... Go to PubMed...
    10. Matoušková M, Hanuš M. Bisfosfonáty v léčbě kostních metastáz v urologii. Urolog. Praxi, 2009; 10(5): 282-286.
    11. Mechl Z, Kostřica R. Bisfosfonáty v léčbě metastatického kostního postižení. Onkologie, 2009; 3(2): 106-110.
    12. Eastham J, McKiernan J, Gleason D, et al. Effect of zoledronic acid on bone pain and skeletal morbidity in patients with advanced prostate cancer: analysis by basaline pain. J Clin Oncol., 2005; 23(Suppl): 393. Go to original source...
    13. Saad F, Higano CS, Sartor O, et al. The role of bisphosphonates in the treatment of prostate cancer. Recommendations from an expert panel. Clin Genitourin Cancer, 2006; 4: 257-262. Go to original source... Go to PubMed...
    14. National Comprehensive Cancer Network. Prostate Cancer 2007. Clinical Practice Guidelines in Oncology.Jenkintown, PA.: NCCN, 2007: 1-48.
    15. Pacík D. Význam inhibice RANK ligandu v léčbě kostních komplikací u pacientů s metastazujícím karcinomem prostaty. Urolog. listy, 2010; 8(4): 58-61.
    16. Fizazi K, Carducci MA, Smith M, et al. A randomized phase III trial of denosumab versus zoledronic acid in patients with bone metastases from castration-resistant prostate cancer. J Clin Oncol, 2010; 28(Suppl): 18. Go to original source...

    Return to the content


    Urology for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.